Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
9 lessons
8mSetmelanotide is a melanocortin-4 receptor agonist peptide, approved only for specific rare causes of obesity. In 2026 its label expanded to acquired hypothalamic obesity after the TRANSCEND phase 3 trial. Here's how it differs from GLP-1 drugs and what the label warns about.
11mEloralintide is Eli Lilly's once-weekly selective amylin receptor agonist. It produced up to 20.1% average weight loss at 48 weeks in Phase 2, and up to 23.3% when paired with tirzepatide. It is not approved anywhere, and its Phase 3 program will not read out before 2028.
9mNew Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.
9mEveryone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.
10mPhase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
9mPhase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.
10mTRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.
12mRetatrutide is Lilly's investigational GIP/GLP-1/glucagon triple agonist. This hub covers what it is, what the trials actually reported about dosing and weight loss, how vial math works, where approval stands, and links to every retatrutide guide on PeptIQ.io.
10mRetatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.
Also available at /blog for legacy links.